Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis.
about
New target for inhibition of bacterial RNA polymerase: 'switch region'Exploring the mode of action of bioactive compounds by microfluidic transcriptional profiling in mycobacteriaDiscovery of Q203, a potent clinical candidate for the treatment of tuberculosis.Complexation of clofazimine by macrocyclic cucurbit[7]uril reduced its cardiotoxicity without affecting the antimycobacterial efficacy.EthA/R-Independent Killing of Mycobacterium tuberculosis by Ethionamide.para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosisKilling kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy.Peptide deformylase--a promising therapeutic target for tuberculosis and antibacterial drug discovery.Docking-based virtual screening of known drugs against murE of Mycobacterium tuberculosis towards repurposing for TB.Screening strategies for discovery of antibacterial natural products.Resistance to rifampicin: a review.Natural products as probes in pharmaceutical research.Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents.Recognizing drug targets using evolutionary information: implications for repurposing FDA-approved drugs against Mycobacterium tuberculosis H37Rv.Comparison of the safety, tolerability, and pharmacokinetics of fidaxomicin in healthy Japanese and caucasian subjectsTotal synthesis of the protected aglycon of fidaxomicin (tiacumicin B, lipiarmycin A3).X-ray crystal structures of Escherichia coli RNA polymerase with switch region binding inhibitors enable rational design of squaramides with an improved fraction unbound to human plasma protein.Novel rapidly diversifiable antimicrobial RNA polymerase switch region inhibitors with confirmed mode of action in Haemophilus influenzae.Final Demonstration of the Co-Identity of Lipiarmycin A3 and Tiacumicin B (Fidaxomicin) through Single Crystal X-ray Analysis.The transcription inhibitor lipiarmycin blocks DNA fitting into the RNA polymerase catalytic siteAntimicrobial activities of fidaxomicinFidaxomicin is an inhibitor of the initiation of bacterial RNA synthesisFidaxomicin jams Mycobacterium tuberculosis RNA polymerase motions needed for initiation via RbpA contacts.Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial.Characterization of a Sugar-O-methyltransferase TiaS5 Affords New Tiacumicin Analogues with Improved Antibacterial Properties and Reveals Substrate Promiscuity
P2860
Q24634933-3D543256-B750-4E3C-96F2-D92EC0ADC370Q28535015-D9F02593-6BB1-40EE-A074-68C6B102163CQ30352594-87634505-12CE-41A5-AD2E-1AFE03EA76A0Q31116166-E6CCDDAF-7B41-4812-89FE-AAA62A2DB5E4Q33599760-4AC64105-95ED-4C61-9A00-0BCB9E284D15Q34351796-4C8278AF-BBE1-4A81-A706-0B64BB78F2B4Q35199072-8A995ACF-B550-4B88-9397-5EA758BF1835Q35561761-33802BAD-DDD2-40F9-A026-40D195225BFEQ37521070-22A156F0-8121-44DD-9DA5-203D5A56FF65Q37644425-132F2A50-6324-49B4-AD06-DE2D1CF30AE2Q37912224-3B40362B-1E82-434B-8A39-D40C9802779AQ38239459-16968AE6-EC94-42AD-A529-0D8DF0FFFD65Q38599715-756FCFBA-BB2D-4EA2-B06D-96C5B4088E7BQ38719092-4B10C4FC-ED98-4078-9745-6CAB649D32F9Q38920104-B5A9988C-3341-44DB-A63A-316AB9B40247Q40475389-D7D1B245-43E7-4AB8-A55E-7EC0FC62DE87Q41233521-C4F338A6-D16C-4C0A-8085-FE8C9F222C1FQ41644940-84CDEEF6-360C-44D5-A1DF-653DF5D6B2BBQ41819896-E658B38E-F3BD-4B42-BCBE-4F1A2867E884Q41850396-D4B48793-0AC3-4D3F-ABA2-2B55EB124A2CQ41860568-C68EA2C3-2A03-4FA6-B9DA-89F699FE4F48Q42118811-AC168F8C-F317-4578-B967-8265607491E1Q42222510-23D4BAD6-C558-4E4A-AA31-89492E73B22EQ42222521-BCF52EEB-3F9A-45C7-9E4B-B3D07F25F675Q52372962-E7894DAB-0A9F-4631-9EF0-EFCB3FAAF81BQ53408541-F262BEED-4690-4A2D-AC9E-F7F86C277A77Q58339057-C4BC6AAE-329B-4606-9CBB-626D6AEE7AB4
P2860
Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Lipiarmycin targets RNA polyme ...... of Mycobacterium tuberculosis.
@en
Lipiarmycin targets RNA polyme ...... of Mycobacterium tuberculosis.
@nl
type
label
Lipiarmycin targets RNA polyme ...... of Mycobacterium tuberculosis.
@en
Lipiarmycin targets RNA polyme ...... of Mycobacterium tuberculosis.
@nl
prefLabel
Lipiarmycin targets RNA polyme ...... of Mycobacterium tuberculosis.
@en
Lipiarmycin targets RNA polyme ...... of Mycobacterium tuberculosis.
@nl
P2093
P2860
P356
P1476
Lipiarmycin targets RNA polyme ...... of Mycobacterium tuberculosis.
@en
P2093
Bangalore L Suresh
David Beer
Esther K Schmitt
Frank Petersen
Jan Jiricek
John E Knox
Mekonnen Kurabachew
Michael Cynamon
Ngai Ling Ma
P2860
P304
P356
10.1093/JAC/DKN269
P407
P577
2008-06-27T00:00:00Z